Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …
processes, including the regulation of transcription, apoptosis and the DNA damage …
[HTML][HTML] Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer
L Yang, HJ Xie, YY Li, X Wang, XX Liu… - Oncology …, 2022 - spandidos-publications.com
Cisplatin is one of the most effective chemotherapy drugs for ovarian cancer, but resistance
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer
PURPOSE The phase III POLO study demonstrated significant progression-free survival
(PFS) benefit for active olaparib maintenance therapy versus placebo for patients with …
(PFS) benefit for active olaparib maintenance therapy versus placebo for patients with …
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
Potential clinical utility of liquid biopsies in ovarian cancer
JW Zhu, P Charkhchi, MR Akbari - Molecular cancer, 2022 - Springer
Background Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. One
of the main challenges in the management of OC is the late clinical presentation of disease …
of the main challenges in the management of OC is the late clinical presentation of disease …
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international …
R Kristeleit, A Lisyanskaya, A Fedenko… - The Lancet …, 2022 - thelancet.com
Background Few prospective studies have compared poly (adenosine diphosphate-ribose)
polymerase (PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated or …
polymerase (PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated or …
Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline
PA Konstantinopoulos, B Norquist… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To provide recommendations on genetic and tumor testing for women diagnosed
with epithelial ovarian cancer based on available evidence and expert consensus …
with epithelial ovarian cancer based on available evidence and expert consensus …
[HTML][HTML] ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Background Homologous recombination repair deficiency (HRD) is a frequent feature of
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …